Medical Oncologist
Advanced liver cancer
Targeted Therapy for — Liver Cancer (HCC)
Targeted therapy is an established option for advanced liver cancer. It works differently from chemotherapy — by cutting off the blood supply tumours need to grow. Which drug fits you depends on your liver function, a blood protein called AFP, and whether treatment has been tried before.
Medically reviewed by Dr. Bharati Devi Gorantla, Medical Oncologist, MBBS · MD · DM (Adyar, Chennai) · ECMO · MRCP SCE (UK) · Last reviewed August 2026
- Pathway-based, not mutation-driven — Most liver cancer targeted drugs block blood vessel growth signals. A specific gene mutation is not required to be eligible.
- Liver function decides eligibility — Your Child-Pugh score — a measure of how well your liver works — determines which drugs are safe to use.
- AFP level matters — This blood protein is routinely measured and guides which second-line drug you may be offered.
- Mostly taken as tablets at home — The main liver cancer targeted drugs are daily oral tablets, not hospital infusions.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Targeted therapy for advanced liver cancer mainly works by blocking blood vessel growth that tumours depend on. NCCN recommends several options — sorafenib and lenvatinib are used first, regorafenib and cabozantinib after disease progression. Eligibility depends on your liver function and AFP level, not a specific gene mutation.
What do the key terms in your liver cancer treatment plan mean?
- HCC (Hepatocellular Carcinoma)
- The most common type of primary liver cancer, starting in the main liver cells called hepatocytes.
- AFP (Alpha-fetoprotein)
- A protein produced by liver tumour cells and measured by a routine blood test. A high AFP level, as defined in NCCN guidance, determines eligibility for one specific second-line targeted drug.
- Child-Pugh score
- A scoring system that classifies how well your liver is functioning, using blood test results and clinical signs. Most targeted therapy trials enrolled only people with Child-Pugh A — near-normal liver function.
- VEGF and VEGFR
- Proteins that signal tumours to grow new blood vessels. Most liver cancer targeted drugs block these signals, which is intended to starve the tumour of its blood supply.
- TKI (Tyrosine Kinase Inhibitor)
- The class of drug that sorafenib, lenvatinib, regorafenib, and cabozantinib belong to. TKIs are taken as daily oral tablets and block multiple growth signals at once.
- BCLC staging
- A staging system specific to liver cancer that links the extent of disease to recommended treatment options. NCCN and ESMO reference BCLC to guide which treatments are appropriate at each stage.
- PD-L1 / MSI-H
- Markers tested from biopsy tissue when an immunotherapy drug is being considered alongside targeted therapy. They are not required for standard targeted drug eligibility in HCC.
Which tests does your team run before starting targeted therapy for liver cancer?
- Liver function tests and Child-Pugh or ALBI scoring — to confirm adequate liver reserve for the drug being considered
- AFP blood test — the result influences which drugs you may be offered at each line of treatment
- Hepatitis B and C blood tests — viral hepatitis must be assessed and, if active, managed before systemic therapy begins
- CT or MRI of chest, abdomen and pelvis — to confirm stage and establish a baseline for measuring response
- Blood pressure measurement — many liver cancer targeted drugs cause significant blood pressure elevation
- Full blood count and kidney function — to detect any baseline problems that affect dosing
- PD-L1 or MSI testing on biopsy tissue — if a combination regimen that includes immunotherapy is being considered
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Get a straight answer from a specialist
45 minutes, your reports reviewed, your questions answered in plain language.
Which drugs does NCCN recommend for advanced liver cancer?
For unresectable or metastatic HCC with preserved liver function, NCCN lists sorafenib and lenvatinib as first-line targeted therapy options. Some first-line regimens now pair a checkpoint inhibitor with a drug that blocks blood vessel growth — your oncologist will explain whether a combination or a single agent fits your situation.
If the disease progresses after first-line treatment, NCCN-listed second-line options include regorafenib (for people who tolerated sorafenib), cabozantinib, and ramucirumab. Ramucirumab is indicated specifically for people with a high AFP level as defined in NCCN guidance.
Unlike lung or colorectal cancer, liver cancer targeted therapy does not depend on finding a specific gene mutation first. The three things that shape the decision are your liver function score, your AFP level, and which treatment you have already received.
What side effects do liver cancer targeted drugs cause?
The most distinctive side effect of most HCC targeted drugs is hand-foot skin reaction — redness, soreness, and sometimes peeling on the palms and soles. Reporting it early means your team can manage it before it limits daily activity.
High blood pressure is common on these drugs. Your team will check it at regular visits and may prescribe or adjust medication to keep it in a safe range throughout treatment.
Fatigue, reduced appetite, and diarrhoea also occur. Because many people starting targeted therapy for HCC already have some degree of underlying liver disease, liver enzyme levels are checked regularly — a change in these results sometimes means a dose adjustment is needed.
Explore 119 more Targeted Therapy Basics, Testing & Your Cancer Type topics
Cancer-Type Specific Targeted Therapy
- CML Treatment with TKIs: Living a Normal Life Span
- Cancer of Unknown Primary: Can Molecular Testing Help?
- GIST Treatment: Why This Cancer Changed Targeted Therapy Forever
- Targeted Therapy for Bile Duct Cancer (Cholangiocarcinoma)
- Targeted Therapy for Bladder and Urothelial Cancer
- Targeted Therapy for Brain Tumours and Glioma
- Targeted Therapy for Breast Cancer: HER2, HR+ and Triple Negative
- Targeted Therapy for CLL and Lymphoma
- Targeted Therapy for Cervical and Endometrial Cancer
- Targeted Therapy for Childhood Cancers
- Targeted Therapy for Colorectal Cancer: RAS, BRAF and HER2
- Targeted Therapy for Head and Neck Cancer
- Targeted Therapy for Kidney Cancer (RCC)
- Targeted Therapy for Liver Cancer (HCC)
- Targeted Therapy for Lung Cancer: Every Mutation and Drug Explained
- Targeted Therapy for Melanoma: BRAF and MEK Inhibitors
- Targeted Therapy for Multiple Myeloma
- Targeted Therapy for Neuroendocrine Tumours
- Targeted Therapy for Ovarian Cancer: PARP Inhibitors and Beyond
- Targeted Therapy for Pancreatic Cancer: Limited but Real Options
- Targeted Therapy for Prostate Cancer
- Targeted Therapy for Sarcoma
- Targeted Therapy for Stomach and Gastroesophageal Cancer
- Targeted Therapy for Thyroid Cancer
- Targeted Therapy in AML: Beyond Standard Chemotherapy
- Tumour-Agnostic Drugs: When the Mutation Matters More Than the Organ
Before You Start - Preparation & Baseline
- 25 Questions to Ask Your Oncologist Before Starting Targeted Therapy
- Before You Start Targeted Therapy: The Complete Preparation Checklist
- Dental Check-Up Before Cancer Treatment: Why It Matters
- Financial Planning Before Starting Long-Term Targeted Therapy
- How Long After Surgery Can You Start Targeted Therapy?
- How to Store Your Targeted Therapy Tablets Correctly
- Setting Up a Dosing Routine You Won't Forget
- Should Targeted Therapy Be Taken With Food or on an Empty Stomach?
- Vaccinations Before and During Cancer Treatment
- What to Expect in Your First Month on Targeted Therapy
- Which Baseline Tests Are Done Before Starting a TKI?
- Which of Your Existing Medicines Must Stop Before Targeted Therapy
- Why You Need an ECHO and ECG Before Certain Cancer Drugs
Biomarker & Molecular Testing
- Can Mutation Testing Be Done on an Old Biopsy Block or Slides?
- Cost of NGS and Mutation Testing in India: 2026 Price Guide
- Do I Need Genetic Testing Before Starting Targeted Therapy?
- Germline vs Somatic Testing: The Difference Nobody Explains Properly
- Getting a Second Opinion on Your Genomic Report
- How Long Do Mutation Test Results Take in India? Realistic Timelines
- How to Read Your Molecular Pathology Report, Line by Line
- IHC, FISH, PCR or NGS: Which Mutation Test Is Right for Your Cancer?
- Is Mutation Testing Worth It If I Can't Afford the Drug?
- Liquid Biopsy vs Tissue Biopsy: Which Test Do You Need?
- My Report Says a Mutation Is 'Actionable': What Does That Mean?
- No Mutation Found in My Report: What Are My Options Now?
- Should I Start Chemotherapy While Waiting for Mutation Results?
- Should You Repeat Molecular Testing After Your Cancer Progresses?
- Single-Gene Test or Full Panel? How to Choose Without Wasting Money
- What Are PD-L1, TMB and MSI, and Do They Affect Targeted Therapy?
- What Does 'Variant of Uncertain Significance' (VUS) Mean?
- What Happens If There Isn't Enough Tissue for Mutation Testing?
- What Is NGS (Next-Generation Sequencing) Testing in Cancer?
- What Is a Molecular Tumour Board and Why Should You Want One?
- Which Cancers Should Always Be Tested for Mutations? A Checklist
- ctDNA and MRD Testing: Tracking Cancer Through a Blood Test
Foundations & How Targeted Therapy Works
- Adjuvant and Neoadjuvant Targeted Therapy: Treatment Before or After Surgery
- Antibody-Drug Conjugates (ADCs): The Smart Bombs of Cancer Treatment
- Biosimilars and Generic Targeted Therapy Drugs: What They Are
- Can Targeted Therapy Be Combined with Chemotherapy or Radiation?
- Can Targeted Therapy Cure Cancer? An Honest Answer
- First-Line, Second-Line and Beyond: How Treatment Lines Work
- How Doctors Decide Between Chemo, Immunotherapy and Targeted Therapy
- How Does Targeted Therapy Actually Work? Explained Without Jargon
- How Long Does Targeted Therapy Take to Start Working?
- Is Targeted Therapy Painful? What the Treatment Actually Feels Like
- Is Targeted Therapy a Type of Chemotherapy? Clearing Up the Confusion
- Oral Tablets vs IV Infusion Targeted Therapy: What's the Difference?
- Precision Oncology vs Personalised Medicine: Are They the Same Thing?
- Targeted Therapy Success Rates: What the Numbers Really Mean
- Targeted Therapy for Stage 4 Cancer: What You Can Realistically Expect
- Targeted Therapy vs Chemotherapy: 12 Differences That Actually Matter
- Targeted Therapy vs Immunotherapy: Which One Is Right for You?
- The 8 Main Types of Targeted Therapy Drugs (With Examples)
- What Do Cancer Drug Endings Like -nib, -mab and -tinib Mean?
- What Is Targeted Therapy for Cancer? A Complete Patient Guide
- Which Cancers Can Be Treated with Targeted Therapy? Full List
- Why Didn't My Doctor Recommend Targeted Therapy for Me?
Mutation & Target-Specific Pages
- ALK-Positive Lung Cancer: Drugs, Response and What Comes Next
- Antiangiogenic Drugs (VEGF Inhibitors): How Starving a Tumour Works
- BCR-ABL and the Philadelphia Chromosome in CML
- BRAF V600E Mutation: Targeted Therapy Across Multiple Cancers
- BRCA vs HRD Testing: Which One Determines PARP Inhibitor Eligibility?
- BRCA1 and BRCA2 Mutations in Cancer Treatment: PARP Inhibitors
- BTK Inhibitors in CLL and Lymphoma
- CD20, CD38 and Other Antibody Targets in Blood Cancers
- CDK4/6 Inhibitors in Hormone-Positive Breast Cancer
- Co-Mutations: When You Have Two Mutations at Once
- EGFR Exon 20 Insertion: Why It's Different and Harder to Treat
- EGFR Mutation in Lung Cancer: Complete Patient Guide
- ESR1 Mutation: Why Your Hormone Therapy Stopped Working
- FGFR Alterations in Bladder and Bile Duct Cancer
- FLT3 Mutation in AML: What It Means for Your Prognosis
- HER2 Mutation in Lung and Gastric Cancer
- HER2-Low Breast Cancer: A New Category That Changes Treatment
- HER2-Positive Breast Cancer: The Full Targeted Therapy Roadmap
- IDH1 and IDH2 Mutations in Glioma, AML and Bile Duct Cancer
- KIT and PDGFRA Mutations in GIST
- KRAS G12C Mutation: The Target That Was Undruggable for 40 Years
- KRAS Mutation but Not G12C: What Are My Options?
- MET Exon 14 Skipping and MET Amplification Explained
- MSI-High and Mismatch Repair Deficiency: Testing and Treatment
- NRG1, MET, RET and Other Rare Fusions: Where to Get Tested
- NTRK Fusion: One Drug for Many Different Cancers
- Osimertinib: What to Expect, Side Effects and How Long It Works
- PALB2, ATM and Other BRCA-Like Genes: Do They Get the Same Drugs?
- PIK3CA Mutation in Breast Cancer: Alpelisib and What to Expect
- PSMA and AR-Targeted Therapy in Prostate Cancer
- RET Fusion Cancer: Lung, Thyroid and Beyond
- ROS1-Positive Cancer: A Rare Mutation with Excellent Options
- TP53 Mutation: Why There's Still No Targeted Drug for It
- Understanding Variant Allele Frequency (VAF) in Your Report
- What If My Mutation Has No Approved Drug Yet?
- mTOR Inhibitors in Cancer: Everolimus and Temsirolimus
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
Why do I not need a gene mutation test before starting targeted therapy for liver cancer?
Most liver cancer targeted drugs work on blood vessel growth signals that almost all HCC tumours use to sustain themselves, rather than on a mutation that only some tumours carry. That is why eligibility does not depend on finding a specific genetic change. The tests that matter for this cancer — liver function, AFP level, and hepatitis status — are blood tests rather than molecular tumour profiling.
What is Child-Pugh A and why does it keep coming up?
Child-Pugh is a scoring system that grades how well your liver is working. Child-Pugh A means near-normal liver function, B means moderate impairment, and C means severe impairment. Most clinical trials of targeted drugs in HCC enrolled people with Child-Pugh A only, so the evidence for benefit and for safe dosing is strongest in that group. If your score is B or C, your oncologist will weigh the available evidence and your overall condition carefully before recommending a systemic drug.
My AFP level is very high — does that mean my cancer is more advanced?
A high AFP level reflects tumour activity in your liver, but it is not a direct measure of how far the cancer has spread. It is one factor among several, not a verdict on its own. In treatment planning, a high AFP level — as defined in NCCN guidance — determines eligibility for one specific second-line drug. Your oncologist will explain what your result means in the context of your full picture, including your imaging and liver function.
Will I have to go to hospital every day for targeted therapy?
No — the main liver cancer targeted drugs are daily oral tablets you take at home. You will need regular clinic visits for blood tests, blood pressure checks, and imaging to see how treatment is working, but there is no daily hospital attendance. Some combination regimens include an intravenous component given as a day-care infusion at set intervals, which your team will schedule in advance.
Can immunotherapy be combined with targeted therapy for liver cancer?
Yes. For some patients, NCCN lists combination regimens pairing a checkpoint inhibitor with a drug that blocks blood vessel growth as a preferred first-line option. Not everyone is suitable — your oncologist will assess your liver function, portal vein status, any autoimmune history, and other factors before recommending a combination. If a combination is planned, additional testing including PD-L1 or MSI assessment may be arranged on your biopsy tissue.
What happens if the first targeted therapy stops working?
Progression on a first-line targeted drug does not mean treatment is over. NCCN lists several second-line options, and the best fit depends on which drug you received first, your liver function at that point, and your AFP level. Your oncologist will reassess all of these at each follow-up imaging result and plan the next step accordingly. Second-line drugs for HCC have established places in international treatment guidelines.